Regeneron Showcases Major Hematology Breakthroughs at ASH 2025

Pune, India | November 17, 2025 Regeneron Pharmaceuticals announced that it will share compelling new data across 14 abstracts at the upcoming American Society of Hematology (ASH) 2025 Annual Meeting, being held in Orlando, Florida, from December 6 to 9. The company says these findings reflect significant advances in blood cancer treatment and rare blood disorder care, reinforcing its leadership in hematology drug development. According to Regeneron, one of the standout revelations is expected to come from its bispecific antibody, Lynozyfic (linvoseltamab-gcpt). In a Phase 1/2 clinical trial named LINKER MM4, Lynozyfic was tested as a monotherapy for patients with newly diagnosed multiple myeloma. Notably, this is the first trial of a BCMA×CD3 bispecific antibody in a frontline myeloma setting. In addition, Regeneron will present updated data from its ongoing LINKER MM2 study, in which Lynozyfic was combined with two different anti-CD38 monoclonal antibodies in patients whose multiple myeloma had relapsed or proved refractory. These two presentations, the company says, could help redefine treatment options early in the disease course. Beyond multiple myeloma, Regeneron is also highlighting advances in lymphoma. The company will report results from its odronextamab program, including an oral presentation on data from its OLYMPIA-3 trial. In this study, odronextamab was given in combination with chemotherapy — and notably, without rituximab — as a frontline therapy for diffuse large B-cell lymphoma (DLBCL). Other data on odronextamab will cover follicular lymphoma (FL), with presentations from the OLYMPIA-2 trial (frontline treatment) as well as OLYMPIA-5 (relapsed or refractory disease), where odronextamab was combined with lenalidomide. These findings may help expand the role of bispecific antibodies in first-line lymphoma therapy. Aside from cancer, Regeneron is also spotlighting progress in rare blood disorders. The company will present updated results from a novel combination therapy of cemdisiran with pozelimab in patients with paroxysmal nocturnal hemoglobinuria (PNH). This head-to-head data versus ravulizumab could influence future standards of care in this complement-mediated disease. Moreover, Regeneron’s pipeline features first-in-human data for REGN7257, targeting patients with severe aplastic anemia who have not responded to, or have relapsed after, immunosuppressive therapy. The early safety and efficacy findings are expected to generate significant interest, given the high unmet need in this patient population. L. Andres Sirulnik, M.D., Ph.D., Senior Vice President and Head of Hematology Clinical Development at Regeneron, described this as a “landmark year” for the company’s hematology program. He noted that the oral presentations of Lynozyfic and frontline odronextamab show how earlier interventions using innovative therapies could benefit more patients. Sirulnik added that the updated data across Regeneron’s blood disorder portfolio “reinforce our strategy of translating our deep expertise in hematology into meaningful progress where unmet needs remain.” To engage with investors and other stakeholders, Regeneron will host a virtual “Regeneron Roundtable” on December 10 at 8:30 a.m. ET. The company expects to provide more details on its multiple myeloma development program during that event. Regeneron’s broad presence at ASH 2025 underscores its ambition to tackle a range of blood cancers and disorders. From bispecific antibodies to RNA-based approaches, its pipeline reflects the company’s commitment to innovation. If these data confirm early promise, they could reshape future hematology treatment paradigms — offering new hope to patients with multiple myeloma, lymphoma, PNH, and aplastic anemia.